Global competition for China’s biotechnology innovations is entering a more aggressive phase as venture capital firms increasingly shift their focus toward early stage scientific research rather than waiting for assets to reach commercialization. Investors, particularly from the United States, are embedding themselves directly
China’s push into advanced robotics manufacturing has entered a new phase as a high capacity humanoid robot factory in Guangdong begins operations, signaling a shift toward industrial scale production. The facility, developed through a partnership between Leju Robotics and Dongfang Precision Science and
Hong Kong based CK Life Sciences is preparing to advance its cancer vaccine pipeline into mainland China using a faster clinical development pathway as the country expands support for early stage drug innovation. Backed by the business empire of Li Ka-shing, the company
Chinese biotechnology company Hangzhou Diagens Biotechnology is expanding the use of artificial intelligence driven chromosome testing to improve efficiency in in vitro fertilisation and strengthen its commercial growth strategy. The initiative comes as China faces declining birth rates and increasing demand for assisted
China military robots are shifting toward coordinated canine robots designed for urban warfare, with swarm tactics, sensors, and networked command evolving fast.
China’s humanoid robotics sector is advancing rapidly but still lacks a transformative breakthrough comparable to the rise of large language models, according to industry experts. Speaking at a major technology forum in Hainan, researchers and executives said the industry has yet to reach
China’s pharmaceutical sector is rapidly moving into the global weight loss drug race after the expiration of Novo Nordisk’s semaglutide patent in the country, unlocking a major commercial opportunity for domestic developers. The shift comes as demand for obesity treatments surges worldwide and
China’s leading lidar manufacturers are accelerating their transition into robotics, signaling a strategic pivot as the country strengthens its position in the global supply chain for next generation automation technologies. Hesai Group and RoboSense Technology, both major players in automotive sensing systems, are
US researchers and agritech companies are intensifying efforts to revive the struggling wheat sector by developing hybrid and genetically modified seeds designed to boost yields and improve resilience against climate stress. Scientists are experimenting with advanced genetic traits, including drought resistance, as the
Gilead Sciences has agreed to acquire US based biotech firm Ouro Medicines in a deal valued at up to 2.18 billion dollars, gaining access to a promising antibody based treatment originally licensed from China’s Keymed Biosciences. The transaction highlights the growing importance of
